EP Patent

EP2136865A2 — Nasal delivery

Assigned to Optinose Inc · Expires 2009-12-30 · 16y expired

What this patent protects

A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising : a nosepiece (17) for fitting to a nostril of a subject, wherein the nosepiece (17) comprises a tip element (25) which includes a delivery aperture (26) …

USPTO Abstract

A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising : a nosepiece (17) for fitting to a nostril of a subject, wherein the nosepiece (17) comprises a tip element (25) which includes a delivery aperture (26) from which substance is in use delivered into the nasal cavity, and the tip element (25) is at least in part tapered such as to be inclined to a longitudinal axis of the nosepiece (17), with the delivery aperture (28) extending both laterally across the tip element (25) and along a longitudinal extent of the tip element (25); a nozzle (35) through which substance is in use delivered, preferably substantially axially to a longitudinal axis of the nosepiece (17), to the respective nasal cavity; and a delivery unit (37) for delivering substance through the nozzle (35) of the nosepiece (17).

Drugs covered by this patent

Patent Metadata

Patent number
EP2136865A2
Jurisdiction
EP
Classification
Expires
2009-12-30
Drug substance claim
No
Drug product claim
No
Assignee
Optinose Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.